Last reviewed · How we verify
Dexmedetomidine 01
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation of intubated and mechanically ventilated patients in intensive care settings, Procedural sedation for diagnostic and therapeutic procedures, Perioperative anxiolysis and analgesia.
At a glance
| Generic name | Dexmedetomidine 01 |
|---|---|
| Sponsor | Guangzhou General Hospital of Guangzhou Military Command |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Sedation |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to decreased norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. The drug produces dose-dependent sedation without significant respiratory depression, making it suitable for procedural sedation and ICU sedation.
Approved indications
- Sedation of intubated and mechanically ventilated patients in intensive care settings
- Procedural sedation for diagnostic and therapeutic procedures
- Perioperative anxiolysis and analgesia
Common side effects
- Hypotension
- Bradycardia
- Hypertension (transient, dose-dependent)
- Dry mouth
- Headache
- Rebound hypertension on discontinuation
Key clinical trials
- Venous Cannulation Pain to Guide Choice of Anesthetic Method (NA)
- Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in PICU (TIP-15-01) (PHASE2)
- Postpartum Women's Dexmedetomidine Sedation (PHASE4)
- The Influence of Age on Dexmedetomidine Pharmacodynamic (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine 01 CI brief — competitive landscape report
- Dexmedetomidine 01 updates RSS · CI watch RSS
- Guangzhou General Hospital of Guangzhou Military Command portfolio CI